top of page



The current study is a Phase 3, multicenter, randomized, double-blind, sham-controlled,
comparative study of SI-6603 in subjects with LDH. Subjects will receive a single intradiscal
dose of SI-6603 1.25 U or a sham injection as control. Safety will be followed for 12 months
after investigational product administration.

Do you Qualify?

​These questions require a yes answer to qualify.​

  • Are you between 30 and 70 years of age?

  • Are you experiencing leg pain caused by the herniation?

​These questions require a no answer to qualify.​

  • Are you currently pregnant, plan to become pregnant or breastfeeding?

  • Currently suffering from any major illnesses that may require extended hospitalization?

  • In the past year have you suffered with any chronic drug or alcohol abuse?

If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.

bottom of page